Skip to content

OS Therapies OSTX Additional Paid-In Capital

Additional Paid-In Capital at other companies

Immunome logo
ImmunomeIMNM
$1.37B+58.5%
CTO
Citius Oncology, Inc.CTOR
$131.44M+47.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$536.45M+6.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$3.46B+19.6%
WHW
Whitehawk Therapeutics, Inc. Common StockWHWK
$491.63M+2.1%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's additional paid-in capital?
OS Therapies (OSTX) reported additional paid-in capital of $66.72M in Q1 2026.
How has OS Therapies's additional paid-in capital changed year-over-year?
OS Therapies's additional paid-in capital increased by 75.1% year-over-year, from $38.1M to $66.72M.
What is the long-term trend for OS Therapies's additional paid-in capital?
Over 2 years (2023 to 2025), OS Therapies's additional paid-in capital has grown at a 233.3% compound annual growth rate (CAGR), from $5.5M to $61.05M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.